It is believed that in cancer cells, binding of GH with GHR activates receptor associated intracellular domain such as JAK2, which further accelerate activation of oncogenic transcription factors STAT3 and STAT5, and other survival molecules including IRS-1, AKT, and ERK (18–20). The gene discussed is GHR; the disease is cancer.